Vicore to Present at Upcoming Investor Conferences
Stockholm, February 26, 2025 – Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences:
- TD Cowen 45th Annual Health Care Conference
Location: Boston, USA
Format: Presentation and 1×1 meetings
Presentation Date and Time: Tuesday, March 4 at 11:50 AM ET/5:50 PM CET
Webcast: https://wsw.com/webcast/cowen177/vico/2027211
Participants: Ahmed Mousa, CEO; Hans Jeppsson, CFO; Megan Richards, VP of IR
- Leerink Partners Global Healthcare Conference 2025
Location: Miami, USA
Format: Presentation and 1×1 meetings
Presentation Date and Time: Tuesday, March 11 at 1:00 PM ET/7:00 PM CET
Webcast: https://wsw.com/webcast/leerink38/vico/2226949
Participants: Ahmed Mousa, CEO; Megan Richards, VP of IR
- 28th Annual Carnegie Nordic Healthcare Seminar
Location: Stockholm, Sweden
Format: Presentation and 1×1 meetings
Presentation Date and Time: Wednesday, March 12 at 7:00 AM ET/1:00 PM CET
Participants: Ahmed Mousa, CEO; Hans Jeppsson, CFO
Interested parties may also access the webcast replay on the Events & Presentations page of Vicore’s website for 90 days following the conclusion of the event.
For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
The company is publicly listed on the Nasdaq Stockholm exchange (VICO). www.vicorepharma.com